TBIO.jpg
Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
September 12, 2019 16:05 ET | Translate Bio, Inc.
--  Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE)...
TBIO.jpg
Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
July 31, 2019 06:51 ET | Translate Bio, Inc.
-- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into clinical development,...
TBIO.jpg
Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
July 31, 2019 06:50 ET | Translate Bio, Inc.
-- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume...
TBIO.jpg
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
July 15, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
June 26, 2019 07:00 ET | Translate Bio, Inc.
LEXINGTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio to Present at the Jefferies 2019 Healthcare Conference
May 28, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces $47.5 Million Private Placement
May 01, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 29, 2019 08:45 ET | Translate Bio, Inc.
LEXINGTON, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
TBIO.jpg
Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors
April 11, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
TBIO.jpg
Translate Bio Appoints Richard Wooster as Chief Scientific Officer
April 08, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...